Johan Mellergård

771 total citations
22 papers, 394 citations indexed

About

Johan Mellergård is a scholar working on Pathology and Forensic Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Johan Mellergård has authored 22 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 9 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Johan Mellergård's work include Multiple Sclerosis Research Studies (17 papers), Immunotherapy and Immune Responses (5 papers) and T-cell and B-cell Immunology (5 papers). Johan Mellergård is often cited by papers focused on Multiple Sclerosis Research Studies (17 papers), Immunotherapy and Immune Responses (5 papers) and T-cell and B-cell Immunology (5 papers). Johan Mellergård collaborates with scholars based in Sweden, United States and Slovakia. Johan Mellergård's co-authors include Magnus Vrethem, Charlotte Dahle, Jan Ernerudh, Maria C. Jenmalm, Maria Hjorth, Fredrik Piehl, Kaj Blennow, Bob Olsson, Tomas Olsson and Peter Lundberg and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Johan Mellergård

21 papers receiving 390 citations

Peers

Johan Mellergård
Jitesh Rana United States
Ariele L. Greenfield United States
Vita Direnzo Italy
Samantha Loveless United Kingdom
Leoni Rolfes Germany
Vincent Damotte United States
Joakim Bergman Sweden
René M. Gieß Germany
Aidan Droogan United Kingdom
Sebastian Torke Germany
Jitesh Rana United States
Johan Mellergård
Citations per year, relative to Johan Mellergård Johan Mellergård (= 1×) peers Jitesh Rana

Countries citing papers authored by Johan Mellergård

Since Specialization
Citations

This map shows the geographic impact of Johan Mellergård's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Mellergård with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Mellergård more than expected).

Fields of papers citing papers by Johan Mellergård

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Mellergård. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Mellergård. The network helps show where Johan Mellergård may publish in the future.

Co-authorship network of co-authors of Johan Mellergård

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Mellergård. A scholar is included among the top collaborators of Johan Mellergård based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Mellergård. Johan Mellergård is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Piehl, Fredrik, Peter Alping, Simon Englund, et al.. (2024). COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab. Annals of Neurology. 96(4). 678–693. 3 indexed citations
2.
Stenmarker, Margaretha, Elham Hedayati, Kenny A. Rodriguez‐Wallberg, et al.. (2024). Morbidity and mortality among children, adolescents, and young adults with cancer over six decades: a Swedish population-based cohort study (the Rebuc study). The Lancet Regional Health - Europe. 42. 100925–100925. 3 indexed citations
3.
4.
Hellberg, Sandra, Johanna Raffetseder, Mohsen Khademi, et al.. (2023). Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. Nature Communications. 14(1). 6903–6903. 42 indexed citations
5.
Ljungman, Per, Adjmal Nahimi, Arta Dreimane, et al.. (2023). Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study. Journal of Neurology Neurosurgery & Psychiatry. 95(2). 125–133. 16 indexed citations
6.
Longinetti, Elisa, Simon Englund, Joachim Burman, et al.. (2023). Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy. Journal of Neurology Neurosurgery & Psychiatry. 95(2). 134–141. 7 indexed citations
7.
Hellberg, Sandra, Johan Mellergård, Charlotte Dahle, et al.. (2023). Prominent epigenetic and transcriptomic changes in CD4+ and CD8+ T cells during and after pregnancy in women with multiple sclerosis and controls. Journal of Neuroinflammation. 20(1). 98–98. 3 indexed citations
8.
Ernerudh, Jan, et al.. (2023). Dimethyl fumarate treatment in relapsing remitting MS changes the inflammatory CSF protein profile by a prominent decrease in T-helper 1 immunity. Multiple Sclerosis and Related Disorders. 80. 105126–105126. 1 indexed citations
9.
Kim, Min Jung, Sandra Hellberg, Chan Hyun Na, et al.. (2022). RNA-sequencing and mass-spectrometry proteomic time-series analysis of T-cell differentiation identified multiple splice variants models that predicted validated protein biomarkers in inflammatory diseases. Frontiers in Molecular Biosciences. 9. 916128–916128. 3 indexed citations
10.
Hellberg, Sandra, Jesse Huang, Mohsen Khademi, et al.. (2022). Plasma protein profiling reveals dynamic immunomodulatory changes in multiple sclerosis patients during pregnancy. Frontiers in Immunology. 13. 930947–930947. 6 indexed citations
11.
Englund, Simon, Marie Kierkegaard, Joachim Burman, et al.. (2022). Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort. Multiple Sclerosis and Related Disorders. 70. 104481–104481. 9 indexed citations
12.
Piehl, Fredrik, Jan Lycke, Jenny Link, et al.. (2022). Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders. 68. 104220–104220. 7 indexed citations
13.
Longinetti, Elisa, Hannah Bower, Kyla A. McKay, et al.. (2022). COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls. Annals of Clinical and Translational Neurology. 9(9). 1449–1458. 8 indexed citations
14.
Hjorth, Maria, et al.. (2020). Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets. PLoS ONE. 15(2). e0228380–e0228380. 27 indexed citations
15.
Mellergård, Johan, et al.. (2020). Non-Bacterial Thrombotic Endocarditis: A Presentation of COVID-19. SHILAP Revista de lepidopterología. 7(8). 1811–1811. 16 indexed citations
16.
17.
Mellergård, Johan, Anders Tisell, Olof Dahlqvist Leinhard, et al.. (2012). Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis. PLoS ONE. 7(9). e44739–e44739. 17 indexed citations
18.
Mellergård, Johan, Jenny Mjösberg, Maria C. Jenmalm, et al.. (2010). Transcriptional characteristics of CD4+ T cells in multiple sclerosis: Relative lack of suppressive populations in blood. Multiple Sclerosis Journal. 17(1). 57–66. 20 indexed citations
19.
Mellergård, Johan, et al.. (2005). In vitro Th2 deviation of myelin-specific peripheral blood lymphocytes from patients with multiple sclerosis. Journal of Neuroimmunology. 171(1-2). 156–162. 3 indexed citations
20.
Mellergård, Johan, Said Havarinasab, & Per Hultman. (2003). Short- and long-term effects of T-cell modulating agents in experimental autoimmunity. Toxicology. 196(3). 197–209. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jitesh Rana Breakdown of academic impact, for papers by Ariele L. Greenfield Breakdown of academic impact, for papers by Vita Direnzo Breakdown of academic impact, for papers by Samantha Loveless Breakdown of academic impact, for papers by Leoni Rolfes Breakdown of academic impact, for papers by Vincent Damotte Breakdown of academic impact, for papers by Joakim Bergman Breakdown of academic impact, for papers by René M. Gieß Breakdown of academic impact, for papers by Aidan Droogan Breakdown of academic impact, for papers by Sebastian Torke
Rankless by CCL
2026